Investing.com -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock rose 5% after reporting positive results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist being developed for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback